Word on the street.......albeit, might be coming from the corner of Dundas & MacDonald in Belleville...
"Yeah, yeah...great financial results results but no more Aqaziquone! And, wait till Spectrum's R&D hears the latest about Urocidin at the upcoming AUA!!"
On a serious note, what a tuffff sector right now to be rewarded for positive results. See Spectrum's mid aft sp below...
April 26 | Thu Apr 26, 2012 7:45am EDT
April 26 (Reuters) - Spectrum Pharmaceuticals posted a better-than-expected quarterly profit on strong sales of its colon cancer drug, Fusilev.
First-quarter net income rose to $47 million, or 71 cents a share, from $13 million, or 23 cents a share, a year ago.
Excluding items it earned 40 cents a share. Revenue rose 36 percent to $60 million, helped by a 46 percent jump in Fusilev sales.
Analysts on average had expected the company to earn 27 cents a share on revenue of $56.9 million, according to Thomson Reuters I/B/E/S.
Spectrum shares closed at $11.15 on Wednesday on the Nasdaq.
Spectrum Pharmaceuticals, Inc. (SPPI) - NasdaqGS
10.68
0.47(4.26%)2:38PM EDT - Nasdaq Real Time Price
| Day's Range: |
10.63 - 12.00 |
Hopefully I did not offend any Spectrum holders. Quite the opposite in mind (hats off to these quarterly results and hopefully will continue on same growth trend or better with the recent acquisition).
Just bullish on Urocidin! rg